openStrategic design and optimization of Umifenovir analogues: Balancing antiviral efficacy and hERG toxicity against SARS-CoV-2IsrafulHoqueauthorNittuSinghauthorUddiptaGhosh DastidarauthorAlna KuriyickalMartinauthorAkshayJoshiauthorYogeshSardanaauthorRavneetSingh ChawlaauthorNirmalDasauthorBinitaPatraauthorRenugaDeviauthorSatyajeetDasauthorDipankarDasauthorSahilKumarauthorRajesh PRingeauthorKiran KumarBokaraauthorKrishan GopalThakurauthorArindamTalukdarauthorArbidol (ARB, Umifenovir), a broad-spectrum antiviral from Russia, lacks Food and Drug Administration (FDA) approval due to insufficient clinical data and undocumented toxicity concerns. Its indole scaffold, with six unique substitutions, enables optimization for improved efficacy. This study optimized ARB's antiviral potency and safety by modifying the N1, C2, C3, and C4 positions. Antiviral efficacy was evaluated in SARS-CoV-2-infected VERO E6 cells, while optimization was guided by absorption, distribution, metabolism, and excretion (ADME), in vivo pharmacokinetic (PK) and hERG. Early modifications at N1 and C2 produced compounds 10 and 14 (IC50 = 1.5 μM), surpassing ARB (IC50 = 9.0 μM). Further refinements yielded compounds 42 (IC50 = 1.1 μM) and 56 (IC50 = 0.24 μM), resolving hERG toxicity (>30 μM). C3 modifications led to lead compounds 77, 79, and 81 (IC50 = 0.67-0.7 μM), achieving superior potency while eliminating hERG toxicity. Mechanism of entry inhibition and immunofluorescence confirmed compound 77 significantly reduced SARS-CoV-2 within Vero cells, supporting their preclinical potential.2025-05American Chemical Society (ACS)Article

For work being deposited by its own author: In self-archiving this collection of files and associated bibliographic metadata, I grant open the right to store them and to make them permanently available publicly for free on-line. I declare that this material is my own intellectual property and I understand that open does not assume any responsibility if there is any breach of copyright in distributing these files or metadata. (All authors are urged to prominently assert their copyright on the title page of their work.)

For work being deposited by someone other than its author: I hereby declare that the collection of files and associated bibliographic metadata that I am archiving at open) is in the public domain. If this is not the case, I accept full responsibility for any breach of copyright that distributing these files or metadata may entail.

Clicking on the deposit button indicates your agreement to these terms.